KP Rx Research
Investment Thesis
KP Rx is a specialist healthcare investment firm founded in 2023 by Hashan De Silva, who spun the strategy out after leading the healthcare practice at Karst Peak Capital. The firm is 100% founder-owned and targets what it calls the "inflection point of value creation" in healthcare: companies where preclinical studies are complete and early human data affirm safety, allowing the firm to capture seed-stage-like return profiles with materially less clinical and regulatory risk than true early-stage investing. KP Rx's stated thesis is that Australia and New Zealand healthcare innovation is well supported by scientific talent but structurally underfunded by local capital markets, creating a "material historical disconnect between company fundamentals and valuations" that the firm is built to exploit.
Sector Focus
KP Rx invests across eight healthcare sub-categories:
- Small-molecule drugs
- Biological products
- Cell & gene therapies
- Medical devices
- Diagnostic technologies
- AI for healthcare
- Healthcare software / SaaS
- Data and analytics
Stage Focus
The firm targets both private and early-stage public (ASX-listed) healthcare companies, specifically biotech companies at or after Phase 2 clinical trials, and medical device companies at or after regulatory clearance. KP Rx explicitly avoids companies that are still many years from human trials, positioning itself deliberately later than a typical seed or Series A biotech investor while still capturing outsized return potential.
Check Size
Check size is not disclosed on the firm's public materials. The fund targets a concentrated portfolio of 5-10 of ANZ's most promising healthcare companies, implying meaningfully large per-company allocations relative to a diversified early-stage fund.
Lead Tendency
Not explicitly stated in public materials. Given the concentrated portfolio construction (5-10 holdings) and the firm's positioning as a cornerstone investor at the inflection point, KP Rx likely takes significant, possibly lead, positions, but this is unconfirmed.
Recent Activity
KP Rx launched its debut vehicle, the KP Rx Healthcare Opportunities Fund, in late 2023, reported by the AFR as targeting companies "battered by market doubts" despite strong underlying fundamentals. Press coverage from May 2024 (The Australian) indicated the firm had scaled back its original $200M fund target amid market conditions, with early reporting citing roughly $40M banked toward that target around the 2023 launch. Since then, the firm and its founder have maintained a steady drumbeat of media and thought-leadership activity: profile pieces in Livewire and NBR (NZ), a series of biotech-stock-picking roundups through 2024-2025, portfolio-company features on Syntara and CurveBeam AI, a podcast appearance on life science investing in November 2025, and a Syntara 2026 outlook webinar in February 2026. Founder Hashan De Silva is frequently cited for his earlier (pre-KP Rx, Karst Peak-era) investment in Neuren Pharmaceuticals at a ~$70M valuation, now valued at ~$2.4B, which anchors much of the firm's public credibility narrative.
Portfolio Highlights
KP Rx's public portfolio page lists six companies:
- Kitea Health
- Navi Medical Technologies
- Syntara (ASX: SNT) - biotech, subject of repeated media coverage and a 2026 outlook webinar
- CurveBeam AI - ASX-listed medtech, profiled by Livewire as "positioned for growth"
- Skin2Neuron
- Inventia Life Science
Neuren Pharmaceuticals is not listed as a KP Rx portfolio company (the investment predates the firm's founding, from De Silva's time at Karst Peak) but is used extensively in the firm's marketing as evidence of track record.
Team
- Hashan De Silva, Founder & Managing Partner: Previously Head of Healthcare at Karst Peak Capital, Lead Healthcare Analyst at CLSA Australia, Associate Healthcare Analyst at Macquarie Bank, and an alumnus of Eli Lilly. Served as a Lieutenant in the Australian Army Reserves (2006-2014). Holds a Bachelor's in Medicine and a Master's in Finance from UNSW; CFA Charterholder.
- Michael Slaven, COO: Formerly on NSW Treasury Corporation's Partner Selection team and roughly seven years at Willis Towers Watson as Associate Director heading Australian Equities, covering private equity and emerging-market equities. Holds a Bachelor of Arts/Commerce and Master of Financial Management from ANU; CFA Charterholder.
- Cameron Jones, CFO: Founding and Managing Director of Bio101. A Chartered Accountant who serves as CFO and Company Secretary for multiple ASX-listed and VC-backed healthcare companies through IPOs, capital raisings, and M&A. Holds a Bachelor of Business from Monash University and a Diploma in Financial Planning.
- Val Moingeon, Principal: Over 15 years of experience across biotechnology, pharmaceutical, and private-equity-backed healthcare sectors, with prior commercial roles at Janssen and Sanofi focused on market access and licensing, and corporate development experience at Novotech. Trained as a pharmacist; holds CFA and CAIA credentials.
Decision Process
Not explicitly disclosed. The four-person team (Managing Partner, Principal, COO, CFO) suggests a small partnership-style decision process rather than a large investment committee.
Founder Preferences
KP Rx's public materials emphasize backing "world-class" Australian and New Zealand biotech and medtech teams with de-risked scientific and regulatory profiles - i.e., founders with completed preclinical work, positive early human data, or products already through regulatory clearance, rather than pure scientific-founder teams pre-data.
Geographic Focus
Exclusively Australia and New Zealand (ANZ). The firm has publicly advocated for liberalization of the trans-Tasman investment market to make ANZ healthcare capital flows more efficient.
Fund Structure
KP Rx operates as a closed-ended Venture Capital Limited Partnership (VCLP) with a 10-year fund life, open only to wholesale investors. Cornerstone investors include Karst Peak Capital, Australian family offices, and healthcare entrepreneurs. The fund targets a net IRR of 20% over its life, with a goal of returning the majority of capital to LPs within 4-6 years. The firm is headquartered at Level 29, Chifley Tower, 2 Chifley Square, Sydney, NSW 2000, Australia (ACN 664 742 349, AFSL 700048).